All In Biotech

Free tool

FAERS Monitor: Optison

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020899 or its brand name (Optison, Albumin Human). Reports on generic versions are filed under their own applications.

Reports

141

Serious

46

33% of reports

Hospitalization

17

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness15
  • back pain13
  • chest pain12
  • drug ineffective12
  • no adverse event12
  • nausea11
  • dyspnoea9
  • feeling hot7
  • headache7
  • flushing6
  • off label use6
  • product quality issue6
  • tremor6
  • vomiting6
  • anaphylactic reaction5

Reports by year received

View as table
YearReports
20042
20061
20081
20102
20121
20131
201414
20157
201610
20176
201811
20197
20202
20215
202211
202312
202415
202513
202620

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,018 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
feeling hotSignal717.08.390
anaphylactic reactionSignal513.55.746
no adverse eventSignal129.95.888
chest painSignal129.75.686
flushingSignal68.84.034
back painSignal138.35.078
product quality issueSignal66.63.023
tremorSignal65.42.517
dizzinessSignal154.52.838
dyspnoeaSignal92.41.36
nauseaSignal112.11.25
vomiting61.90.92
headache71.70.81
drug ineffective121.40.81
off label use61.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.